|
1
|
Sirica AE: Cholangiocarcinoma: Molecular
targeting strategies for chemoprevention and therapy. Hepatology.
41:5–15. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Patel T: Increasing incidence and
mortality of primary intrahepatic cholangiocarcinoma in the United
States. Hepatology. 33:1353–1357. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Taylor-Robinson SD, Foster GR, Arora S,
Hargreaves S and Thomas HC: Increase in primary liver cancer in the
UK, 1979–94. Lancet. 350:1142–1143. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Seo E, Abei M, Wakayama M, Fukuda K, Ugai
H, Murata T, Todoroki T, Matsuzaki Y, Tanaka N, Hamada H and
Yokoyama KK: Effective gene therapy of biliary tract cancers by a
conditionally replicative adenovirus expressing uracil
phosphoribosyltransferase: Significance of timing of 5-fluorouracil
administration. Cancer Res. 65:546–552. 2005.PubMed/NCBI
|
|
5
|
Nakano K, Todo T, Chijiiwa K and Tanaka M:
Therapeutic efficacy of G207, a conditionally replicating herpes
simplex virus type 1 mutant, for gallbladder carcinoma in
immunocompetent hamsters. Mol Ther. 3:431–437. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schauer RJ, Meyer G, Baretton G,
Schildberg FW and Rau HG: Prognostic factors and long-term results
after surgery for gallbladder carcinoma: A retrospective study of
127 patients. Langenbecks Arch Surg. 386:110–117. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hayashi N, Yamamoto H, Hiraoka N, Dono K,
Ito Y, Okami J, Kondo M, Nagano H, Umeshita K, Sakon M, et al:
Differential expression of cyclooxygenase-2 (COX-2) in human bile
duct epithelial cells and bile duct neoplasm. Hepatology.
34:638–650. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Itoi T, Shinohara Y, Takeda K, Nakamura K,
Shimizu M, Ohyashiki K, Hisatomi H, Nakano H and Moriyasu F:
Detection of telomerase reverse transcriptase mRNA in biopsy
specimens and bile for diagnosis of biliary tract cancers. Int J
Mol Med. 7:281–287. 2001.PubMed/NCBI
|
|
9
|
Kagaya M, Kaneko S, Ohno H, Inamura K and
Kobayashi K: Cloning and characterization of the 5′-flanking region
of human cytokeratin 19 gene in human cholangiocarcinoma cell line.
J Hepatol. 35:504–511. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kato M, Shinozawa T, Kato S, Endo K and
Terada T: Increased midkine expression in intrahepatic
cholangiocarcinoma: Immunohistochemical and in situ hybridization
analyses. Liver. 20:216–221. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tamada S, Goto M, Nomoto M, Nagata K,
Shimizu T, Tanaka S, Sakoda K, Imai K and Yonezawa S: Expression of
MUC1 and MUC2 mucins in extrahepatic bile duct carcinomas: Its
relationship with tumor progression and prognosis. Pathol Int.
52:713–723. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Afford SC and Young LS: Gene therapy for
hepatocellular carcinoma-teaching old dogs new tricks. Hepatology.
34:207–209. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lie-A-Ling M, Bakker CT, Deurholt T,
Hoekstra R, Wesseling JG, Afford SC and Bosma PJ: Selection of
tumour specific promoters for adenoviral gene therapy of
cholangiocarcinoma. J Hepatol. 44:126–133. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nagi P, Vickers SM, Davydova J, Adachi Y,
Takayama K, Barker S, Krasnykh V, Curiel DT and Yamamoto M:
Development of a therapeutic adenoviral vector for
cholangiocarcinoma combining tumor-restricted gene expression and
infectivity enhancement. J Gastrointest Surg. 7:364–371. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jarnagin WR: Cholangiocarcinoma of the
extrahepatic bile ducts. Semin Surg Oncol. 19:156–176. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Saukkonen K and Hemminki A:
Tissue-specific promoters for cancer gene therapy. Expert Opin Biol
Ther. 4:683–696. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lu B, Makhija SK, Nettelbeck DM, Rivera
AA, Wang M, Komarova S, Zhou F, Yamamoto M, Haisma HJ, Alvarez RD,
et al: Evaluation of tumor-specific promoter activities in
melanoma. Gene Ther. 12:330–338. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Latham JP, Searle PF, Mautner V and James
ND: Prostate-specific antigen promoter/enhancer driven gene therapy
for prostate cancer: Construction and testing of a tissue-specific
adenovirus vector. Cancer Res. 60:334–341. 2000.PubMed/NCBI
|
|
19
|
Nettelbeck DM, Jérôme V and Müller R: Gene
therapy: Designer promoters for tumour targeting. Trends Genet.
16:174–181. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kurihara T, Brough DE, Kovesdi I and Kufe
DW: Selectivity of a replication-competent adenovirus for human
breast carcinoma cells expressing the MUC1 antigen. J Clin Invest.
106:763–771. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wirth T, Zender L, Schulte B, Mundt B,
Plentz R, Rudolph KL, Manns M, Kubicka S and Kühnel F: A
telomerase-dependent conditionally replicating adenovirus for
selective treatment of cancer. Cancer Res. 63:3181–3188.
2003.PubMed/NCBI
|
